Shares of Pharming Group (NASDAQ:PHAR - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $10.75, but opened at $11.48. Pharming Group shares last traded at $11.39, with a volume of 3,990 shares.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 20th. Oppenheimer boosted their price objective on shares of Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a report on Friday, March 14th.
View Our Latest Analysis on PHAR
Pharming Group Stock Up 5.1%
The stock has a market capitalization of $768.55 million, a PE ratio of -43.45 and a beta of 0.02. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The business's fifty day moving average price is $9.63 and its two-hundred day moving average price is $9.18.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The firm had revenue of $79.09 million during the quarter, compared to the consensus estimate of $67.74 million. On average, equities research analysts forecast that Pharming Group will post -0.2 EPS for the current fiscal year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Recommended Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
